Boone Capital Management LLC Acquires 120,963 Shares of LivaNova PLC $LIVN

Boone Capital Management LLC boosted its holdings in LivaNova PLC (NASDAQ:LIVN) by 72.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 288,895 shares of the company’s stock after acquiring an additional 120,963 shares during the period. LivaNova accounts for about 6.0% of Boone Capital Management LLC’s portfolio, making the stock its 9th largest holding. Boone Capital Management LLC’s holdings in LivaNova were worth $17,776,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in LIVN. Artisan Partners Limited Partnership lifted its holdings in LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares during the last quarter. Wellington Management Group LLP lifted its holdings in LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares during the last quarter. Invesco Ltd. lifted its holdings in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after acquiring an additional 902,447 shares during the last quarter. Scopia Capital Management LP acquired a new position in LivaNova in the second quarter valued at approximately $36,657,000. Finally, Millennium Management LLC lifted its stake in LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after purchasing an additional 544,033 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Mizuho upped their price target on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Barclays upped their price target on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Needham & Company LLC upped their price target on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Robert W. Baird decreased their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Stock Performance

NASDAQ:LIVN opened at $78.50 on Thursday. The firm has a market capitalization of $4.31 billion, a PE ratio of 40.26 and a beta of 0.88. The business’s fifty day moving average price is $70.01 and its 200 day moving average price is $66.14. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. LivaNova PLC has a 12 month low of $41.01 and a 12 month high of $80.96.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts anticipate that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.35% of the stock is owned by company insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.